Player FM - Internet Radio Done Right
21 subscribers
Checked 3h ago
Added four years ago
Innhold levert av Proactive Investors. Alt podcastinnhold, inkludert episoder, grafikk og podcastbeskrivelser, lastes opp og leveres direkte av Proactive Investors eller deres podcastplattformpartner. Hvis du tror at noen bruker det opphavsrettsbeskyttede verket ditt uten din tillatelse, kan du følge prosessen skissert her https://no.player.fm/legal.
Player FM - Podcast-app
Gå frakoblet med Player FM -appen!
Gå frakoblet med Player FM -appen!
Phenom Resources CEO highlights promising gold exploration projects in Nevada
Manage episode 456188618 series 2891889
Innhold levert av Proactive Investors. Alt podcastinnhold, inkludert episoder, grafikk og podcastbeskrivelser, lastes opp og leveres direkte av Proactive Investors eller deres podcastplattformpartner. Hvis du tror at noen bruker det opphavsrettsbeskyttede verket ditt uten din tillatelse, kan du følge prosessen skissert her https://no.player.fm/legal.
Phenon Resources CEO Paul Cowley joined Steve Darling from Proactive to provide insights into the company’s strategic gold exploration initiatives across Nevada. Phenom Resources is pursuing a diversified exploration strategy with four active gold projects—Dobbin, King Solomon, Crescent Valley, and West Jerome—each offering unique potential for substantial discoveries. Cowley shared exciting updates from the Dobbin Project, which has shown exceptionally promising results. Describing Dobbin as a “gold deposit discovery,” Cowley pointed to the results of extensive soil profiling and anomaly mapping as key indicators of its potential. “The gold values we’re seeing here are unusually high for Nevada,” he explained, underscoring the project's standout nature. Looking ahead, the company is planning systematic trenching and drilling programs in 2025 to further evaluate and unlock the deposit’s potential. Another standout project, King Solomon, was highlighted for its strong gold potential. Cowley noted that it has already been identified as a gold deposit, and ongoing assessments are focused on determining the resource’s size and scalability. With the involvement of renowned geologist Dave Matthewson, the company is confident in its ability to identify multi-million-ounce opportunities across its portfolio. Phenom Resources is well-positioned to capitalize on Nevada’s mining-friendly jurisdiction, which remains one of the most attractive regions globally for gold exploration. Cowley also emphasized the favorable market outlook for gold prices, which strengthens the company’s optimism for its projects. Reflecting on the company’s progress and future plans, Cowley expressed enthusiasm for what lies ahead. “2025 has the potential to be a breakout year for Phenom Resources. With a world-class team, a diversified portfolio of promising projects, and Nevada’s unparalleled support for mining, we’re poised for significant success,” he shared. As Phenom Resources moves forward, the company is focused on advancing exploration, uncovering new opportunities, and leveraging its expertise to drive value for stakeholders. With multiple projects showing strong potential and strategic plans in place, Phenom is well-prepared to deliver meaningful results in the years to come. #proactiveinvestors #phenomresourcescorp #tsxv #phnm #otcqx #phnm GoldExploration #NevadaMining #DobbinProject #KingSolomon #GoldDiscovery #GoldInvesting #MiningIndustry #2025Exploration #investment #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews
…
continue reading
610 episoder
Manage episode 456188618 series 2891889
Innhold levert av Proactive Investors. Alt podcastinnhold, inkludert episoder, grafikk og podcastbeskrivelser, lastes opp og leveres direkte av Proactive Investors eller deres podcastplattformpartner. Hvis du tror at noen bruker det opphavsrettsbeskyttede verket ditt uten din tillatelse, kan du følge prosessen skissert her https://no.player.fm/legal.
Phenon Resources CEO Paul Cowley joined Steve Darling from Proactive to provide insights into the company’s strategic gold exploration initiatives across Nevada. Phenom Resources is pursuing a diversified exploration strategy with four active gold projects—Dobbin, King Solomon, Crescent Valley, and West Jerome—each offering unique potential for substantial discoveries. Cowley shared exciting updates from the Dobbin Project, which has shown exceptionally promising results. Describing Dobbin as a “gold deposit discovery,” Cowley pointed to the results of extensive soil profiling and anomaly mapping as key indicators of its potential. “The gold values we’re seeing here are unusually high for Nevada,” he explained, underscoring the project's standout nature. Looking ahead, the company is planning systematic trenching and drilling programs in 2025 to further evaluate and unlock the deposit’s potential. Another standout project, King Solomon, was highlighted for its strong gold potential. Cowley noted that it has already been identified as a gold deposit, and ongoing assessments are focused on determining the resource’s size and scalability. With the involvement of renowned geologist Dave Matthewson, the company is confident in its ability to identify multi-million-ounce opportunities across its portfolio. Phenom Resources is well-positioned to capitalize on Nevada’s mining-friendly jurisdiction, which remains one of the most attractive regions globally for gold exploration. Cowley also emphasized the favorable market outlook for gold prices, which strengthens the company’s optimism for its projects. Reflecting on the company’s progress and future plans, Cowley expressed enthusiasm for what lies ahead. “2025 has the potential to be a breakout year for Phenom Resources. With a world-class team, a diversified portfolio of promising projects, and Nevada’s unparalleled support for mining, we’re poised for significant success,” he shared. As Phenom Resources moves forward, the company is focused on advancing exploration, uncovering new opportunities, and leveraging its expertise to drive value for stakeholders. With multiple projects showing strong potential and strategic plans in place, Phenom is well-prepared to deliver meaningful results in the years to come. #proactiveinvestors #phenomresourcescorp #tsxv #phnm #otcqx #phnm GoldExploration #NevadaMining #DobbinProject #KingSolomon #GoldDiscovery #GoldInvesting #MiningIndustry #2025Exploration #investment #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews
…
continue reading
610 episoder
كل الحلقات
×P
Proactive - Interviews for investors
1 Replenish Nutrients secures $1.15M in financing to bolster sustainable fertilizer production 4:57
4:57
Spill senere
Spill senere
Lister
Lik
Likt
4:57Replenish Nutrients CEO Neil Wiens joined Steve Darling to share exciting developments with Proactive, announcing the successful closing of $1.15 million in key debt financings. This pivotal funding will enable critical upgrades to the company’s Beiseker granulation facility, positioning it to meet surging demand for sustainable fertilizer solutions ahead of the crucial spring planting season. Wiens highlighted that the upgrades will allow the facility to achieve full operational capacity, producing 20,000–25,000 metric tonnes of granulated fertilizer annually. These enhancements are expected to be completed by early Q2 2025, perfectly timed to capitalize on the spring fertilizer season, a significant revenue-driving period for the company. Replenish Nutrients has already secured purchase orders for the first 6,000 metric tonnes of production, with an average price of $575 per tonne, yielding impressive gross margins of 25%–35%, consistent with prior guidance. With ongoing demand from long-standing customers and distributors, the company anticipates selling the facility’s full annual capacity, ensuring strong EBITDA and positive operating cash flow on a run-rate basis. Beyond the Beiseker facility, this financing milestone provides momentum for Replenish’s broader growth strategy. Future projects include the planned DeBolt and Bethune granulation facilities, aligning with the company’s mission to scale sustainable agriculture and expand its presence in high-demand markets. #proactiveinvestors #replenishnutrientsholdingscorp #cse #erth #otc #vvivf #RegenerativeAgriculture #FertilizerInnovation #SustainableFarming #CropGrowth #NeilWiens #AgricultureNews #Farming2025 #ProactiveInvestors #SustainableSolutions…
P
Proactive - Interviews for investors
1 NanoViricides advances antiviral drug with Phase II Clinical trial to Combat MPox 4:46
4:46
Spill senere
Spill senere
Lister
Lik
Likt
4:46NanoViricides CEO Dr Anil Diwan joined Steve Darling from Proactive shared pivotal updates with Proactive, announcing the company’s engagement of a Clinical Research Organization to conduct a Phase II clinical trial for its innovative broad-spectrum antiviral therapy. This milestone represents a significant step in advancing the therapy through the regulatory process. The upcoming Phase II trial will evaluate the effectiveness of the therapy in treating MPox, a disease caused by the human Mpox virus that has triggered a regional pandemic in parts of Africa, including the Democratic Republic of Congo and Uganda. In 2024, the World Health Organization declared MPox a Public Health Emergency of International Concern. Currently, no approved treatments exist for infections caused by this virus. The therapy has shown strong antiviral activity in preclinical studies, particularly against an orthopoxvirus model that serves as a critical predictor of efficacy for MPox and Smallpox. Notably, its effectiveness matched that of tecovirimat, a widely recognized antiviral, in both direct skin and lung infection models. Dr. Diwan underscored the potential impact of this therapy in addressing a pressing global health challenge, positioning NanoViricides as a leader in developing innovative treatments for diseases caused by orthopoxviruses. With this trial, the company aims to provide a critical solution to an urgent unmet medical need. #proactiveinvestors #nanoviricidesinc #nyseamerican #nnvc…
P
Proactive - Interviews for investors
1 Critical Minerals: M2i Global CEO talks supply chain strategy after Trump executive order 4:41
4:41
Spill senere
Spill senere
Lister
Lik
Likt
4:41M2i Global CEO Alberto Rosende joined Steve Darling from Proactive to discuss the company’s response to the Executive Order "Unleashing American Energy," signed by U.S. President Donald Trump on January 20, 2025. The order aligns closely with M2i’s mission to enhance domestic critical mineral production, supporting U.S. defense sector resilience and economic growth. Rosende highlighted that the Executive Order accelerates M2i’s ability to expand Joint Venture arrangements and critical mineral partnerships. The company is collaborating with federal facilities and lands to develop a Strategic Mineral Reserve, meeting the mandate to boost domestic production and reduce dependence on foreign supply chains. M2i’s robust ecosystem of partners offers turnkey solutions, enabling business expansion, securing offtake agreements, and driving strategic government policies. The company collaborates with federal and state governments, universities, specialized mining firms, and NGOs to position the U.S. as a global leader in critical minerals processing. The company’s international business model ensures that minerals are ethically sourced, adhere to stringent environmental and labor standards, and are exclusively traded with authorized countries. M2i's partnerships with allies like Australia further strengthen its framework, leveraging advanced technologies to create a strategic reserve for the U.S. defense sector, aligning with President Trump’s vision for energy and resource independence. #proactiveinvestors #m2iglobalinc #otcqb #mtwo #SupplyChain #M2iGlobal #AlbertoRosende #StrategicMineralReserve #RecyclingEconomy #MineralsIndependence #EnergySecurity #ProactiveInvestors #MiningIndustry…
P
Proactive - Interviews for investors
1 Livium CEO on recycling refocus and expansion plans 5:27
5:27
Spill senere
Spill senere
Lister
Lik
Likt
5:27Livium Ltd (ASX:LIT, OTC:LMMFF) managing director and CEO Simon Linge talks with Proactive’s Tylah Tully about the company’s latest updates, focusing on its strategic initiatives and near-term goals. Linge highlighted Livium’s strong emphasis on scaling its battery recycling business to meet the growing influx of large-format lithium-ion batteries, positioning the company as a key player in this growing sector. He discussed two other patented technologies, including LieNA® technology, developed in partnership with Mineral Resources, which is moving to its next phase of development. Additionally, Livium’s battery materials technology has made progress with customer agreements and product portfolio advancements, enabling the company to scale this segment. Linge explained how the organisation was actively pursuing funding opportunities through strategic, public and private partnerships. On restructuring, Linge outlined the ongoing cost-saving measures and workforce changes designed to position Livium for sustainable growth through 2026. He emphasised the company’s commitment to securing battery recycling agreements and a pipeline for large-format battery supplies, which are expected to reach 25,000 tonnes by the end of the decade. Stay tuned for further updates on Livium’s recycling milestones, restructuring developments, and commercialisation efforts. #ProactiveInvestors #LiviumLtd #ASX #OTC #BatteryRecycling #LithiumIonBatteries #EnergyStorage #SustainableTechnology #ASXLIT #BatteryMaterials #CircularEconomy #SimonLinge…
P
Proactive - Interviews for investors
1 Just the Facts: Leeuwin Metals secures A$3.25 million for exploration and Marda acquisition 1:36
1:36
Spill senere
Spill senere
Lister
Lik
Likt
1:36Proactive’s Tylah Tully breaks down ‘Just the Facts’ of the latest news from Leeuwin Metals Ltd (ASX: LM1). Leeuwin Metals has raised A$3.25 million through a two-tranche share placement priced at A$0.098 per share, reflecting an 18.3% discount to the last closing price. The placement attracted strong interest from institutional and sophisticated investors, with contributions of approximately A$250,000 from directors and management, subject to shareholder approval. The placement comprises two tranches: Tranche 1 raised approximately A$1.55 million, while Tranche 2 is expected to raise A$1.7 million, contingent on shareholder approval at an extraordinary general meeting scheduled for February 2025. The funds will support exploration and drilling activities across Leeuwin’s Australian and Canadian project portfolio, working capital and placement costs. A key focus is the Marda Gold Project in Western Australia, which Leeuwin is acquiring from Ramelius Resources. Announced in December 2024, the acquisition is anticipated to conclude in Q1 2025. Leeuwin's management highlighted the strategic significance of the Marda acquisition, located in a renowned goldfield, as a growth opportunity for shareholders. The funding positions the company to advance its exploration programs across its highly prospective assets. #ProactiveInvestors #LeeuwinMetals #GoldMining #CapitalRaising #MardaGoldProject #ASXUpdate #InstitutionalInvestors #SophisticatedInvestors #GoldExploration #WesternAustralia #CanadaMining #MineralResources #SharePlacement #RameliusResources #MineralExploration #MiningProjects #CorporateUpdate #ExplorationFunding #InvestmentOpportunities #GoldFields #ASXNews…
P
Proactive - Interviews for investors
1 Sona Nanotech's cancer treatment study published in peer-reviewed journal Frontiers in Immunology 6:25
6:25
Spill senere
Spill senere
Lister
Lik
Likt
6:25Sona Nanotech CEO David Regan joined Steve Darling from Proactive to share the publication of groundbreaking findings from the company’s pre-clinical breast cancer and melanoma efficacy studies in the prestigious scientific journal Frontiers in Immunology. This comprehensive research highlights the transformative potential of Sona’s Targeted Hyperthermia Therapy (THT) and includes critical new follow-up data on its immune-activating properties. Sona’s proprietary technology employs patented, biocompatible gold nanorods (GNRs) to deliver precision, non-invasive hyperthermia therapy directly to cancer cells. This approach minimizes systemic toxicity, a common drawback of traditional cancer treatments. The study demonstrated that Sona’s THT induces cancer-specific cell death while triggering a robust immune response, marking a significant breakthrough in cancer immunotherapy. Notably, the research revealed that the immune response activated by Sona’s THT is effective against cancers that are typically resistant to modern immunotherapies. This novel immunity offers a critical advantage, paving the way for new treatment possibilities in cases where conventional methods fall short. #proactiveinvestors #sonananotechinc #cse #sona #otcqb #snanf #CancerResearch #GoldNanorods #TargetedTherapy #Biotechnology #CancerTreatment #HyperthermiaTherapy #Immunology #MedicalBreakthroughs #Nanotechnology…
P
Proactive - Interviews for investors
1 AOTI’s Dr Mike Griffiths on breakthrough for diabetic foot ulcers, chronic wound care 7:23
7:23
Spill senere
Spill senere
Lister
Lik
Likt
7:23AOTI Inc (AIM:AOTI) CEO, president, and co-founder Dr Mike Griffiths talked with Proactive about the company’s efforts to revolutionise chronic wound care. AOTI is focused on treating conditions like diabetic foot ulcers with its unique home-based oxygen therapy, designed to promote durable healing. Griffiths highlighted the staggering $80 billion US diabetic foot ulcer care market and shared that AOTI is well-positioned to expand within this space. He noted that AOTI’s strong clinical evidence and ability to reduce hospitalisations and amputations resonate strongly with payers and healthcare providers. He also shared recent milestones, including the company’s expansion into six Medicaid states, its five-year renewal of the Veterans Affairs contract, and ongoing efforts to broaden its international presence. Griffiths announced the start of enrolments for the venous leg ulcer (VLU) clinical trial and discussed its significance in building high-quality evidence for AOTI's therapy. AOTI, headquartered in the US and listed on AIM, has grown by over 30% annually for five years and Griffiths expects this growth to continue as it enters new markets like skilled nursing and long-term care. “We believe we’re in a very exciting sector, with solutions that deliver long-term outcomes,” he shared. Visit Proactive’s YouTube channel for more videos, and don’t forget to like, subscribe, and enable notifications for updates! #AOTI #ChronicWoundCare #DiabeticFootUlcers #MedicalTechnology #HealthcareInnovation #OxygenTherapy #Medicaid #VeteransAffairs #ClinicalTrials #MedTechGrowth…
P
Proactive - Interviews for investors
1 hVIVO partners with ILiAD Biotechnologies for pivotal Phase 3 human challenge trial 6:01
6:01
Spill senere
Spill senere
Lister
Lik
Likt
6:01hVIVO PLC CEO Yamin 'Mo' Khan talked with Proactive's Stephen Gunnion about the company's involvement in a world-first Phase 3 human challenge trial for a pertussis (whooping cough) vaccine candidate. The trial, in partnership with ILiAD Biotechnologies, is expected to start in the second half of this year. Khan highlighted the importance of this milestone for hVIVO, noting that it will be the company's largest challenge trial to date and its first bacterial challenge trial. The trial data aims to secure FDA marketing authorisation, marking a pivotal moment for the utility of human challenge trials in vaccine development. According to Khan, "The goal is to get a better vaccine to patients faster. Pertussis is a severe disease, particularly for infants, and there's an urgent need for new vaccines." He further explained that hVIVO's state-of-the-art Canary Wharf facility will play a critical role in supporting this trial, equipped with expanded laboratory capabilities for bacterial analysis. The trial comes as cases of pertussis are on the rise, increasing sixfold between 2023 and 2024. ILiAD Biotechnologies has also secured FDA fast-track status and an MHRA innovation passport for this vaccine candidate. Khan emphasised the partnership's goal of addressing this unmet medical need and delivering an effective vaccine to patients worldwide. Visit Proactive's YouTube channel for more videos, and don’t forget to like, subscribe, and enable notifications for future updates. #hVIVO #VaccineDevelopment #WhoopingCough #Pertussis #ClinicalTrials #FDAApproval #BiotechInnovation #Phase3Trial #HumanChallengeTrials #HealthcareResearch…
P
Proactive - Interviews for investors
1 Fineqia International CEO unveils first DeFi yield ETP 7:56
7:56
Spill senere
Spill senere
Lister
Lik
Likt
7:56Fineqia International Inc CEO Bundeep Singh Rangar talked with Proactive's Stephen Gunnion about launching the world’s first exchange-traded product (ETP) that deploys digital assets in yield-bearing decentralized finance (DeFi). Rangar explained the product's unique value, providing access to DeFi yield through a transparent, regulated security listed on the Vienna Stock Exchange. The Fineqia FTSE Cardano Enhanced Yield ETN (AV:YADA) is based on the Cardano network, a top ten cryptocurrency valued at over $35 billion, and allows investors to participate in DeFi activities such as borrowing, lending, and validating transactions, which generate fees. Unlike traditional ETFs and ETNs, Fineqia's product reinvests 80% of these yields back to investors, making it a truly innovative approach. Rangar highlighted the importance of partnering with FTSE Russell, a subsidiary of the London Stock Exchange, to ensure robust pricing data for this groundbreaking product. He added, "This is an icebreaker for what we want to do in the industry... We’re about being innovative and different." This collaboration sets a milestone for the ETP industry by combining blockchain technology and traditional finance, giving fund managers and retail investors easy access to decentralized finance through a familiar financial instrument. Visit Proactive's YouTube channel for more videos like this one, and don’t forget to give the video a like, subscribe to the channel, and enable notifications for updates! #Fineqia #DeFi #CryptoETP #DecentralizedFinance #Cardano #DigitalAssets #ETN #CryptoInvesting #Blockchain #FTSERussell…
P
Proactive - Interviews for investors
1 GoviEx Uranium unveils low-risk, high-reward Muntanga feasibility study 4:31
4:31
Spill senere
Spill senere
Lister
Lik
Likt
4:31GoviEx Uranium Inc (TSX-V:GXU, OTCQX:GVXXF) CEO Daniel Major discussed the just-released feasibility study for the Mutanga Uranium project in Zambia with Proactive's Stephen Gunnion. Major highlighted that the study outlines solid project economics, including a net present value (NPV) of $243.00 million and an internal rate of return (IRR) of 20.8% at a uranium price of $90.00 per pound. He described Mutanga as a straightforward open-pit project benefiting from local infrastructure and low technical risks. The company plans to produce 2.20 million pounds of uranium annually over a 12-year lifespan. Major emphasised the potential for resource expansion from nearby satellite deposits, which could further enhance the project’s value. Additionally, he outlined the global uranium market dynamics, noting a deficit in supply and growing demand driven by new reactors, life extensions for existing reactors, and advancements in small modular reactors (SMRs). Looking ahead, GoviEx is targeting project construction by 2028 and is actively seeking debt financing and offtake agreements to move forward. Major said, "We’re already sharing our feasibility study with utilities to ensure we meet their requirements." Watch the full interview to learn more about GoviEx’s strategy for meeting global uranium demand. Don’t forget to like the video, subscribe to Proactive’s YouTube channel, and enable notifications for future updates! #GoviExUranium #MutangaProject #UraniumMining #ZambiaResources #EnergyDemand #UraniumFeasibility #LowRiskMining #GlobalEnergy #NuclearEnergy #SmallModularReactors…
P
Proactive - Interviews for investors
1 ANGLE PLC says Nature Medicine journal highlights Parsortix's role in cancer breakthrough 11:25
11:25
Spill senere
Spill senere
Lister
Lik
Likt
11:25ANGLE PLC (AIM:AGL, OTCQX:ANPCY) CEO Andrew Newland talked with Proactive's Stephen Gunnion about groundbreaking research using the Parsortix system. This system has enabled significant advancements in cancer research, including a recent study published in Nature Medicine that explores stopping the metastatic spread of cancer. Newland explained how Parsortix helps identify and analyse circulating tumour cell clusters, which are critical to cancer progression. He highlighted research led by Professor Nicola Aceto at the Cancer Metastasis Laboratory in Zurich, where they discovered that FDA-approved cardiac drugs could break these clusters into individual cells. In mice and breast cancer patients, this approach showed potential to halt cancer progression. The CEO emphasised Parsortix's central role in identifying patients and monitoring treatment efficacy, predicting global interest and demand for the system. He also discussed ANGLE's broader work with cancer drug developers, including collaborations with companies like AstraZeneca and Eisai, to unlock new approaches to managing cancer. Newland concluded with optimism, envisioning a future where cancer could become a manageable condition, similar to how HIV/AIDS is now controlled. Discover more about this transformative research and ANGLE PLC’s contributions. Like this video, subscribe to Proactive’s channel, and enable notifications for future updates!" #ANGLEPLC #Parsortix #CancerResearch #CancerBreakthrough #Oncology #Metastasis #CirculatingTumorCells #MedicalInnovation #NatureMedicine #CancerAwareness…
P
Proactive - Interviews for investors
1 Iofina CEO on record iodine production in 2024, growth plans 5:31
5:31
Spill senere
Spill senere
Lister
Lik
Likt
5:31Iofina PLC (AIM:IOF, OTC:IOFNF) CEO Dr Tom Becker talked with Proactive's Stephen Gunnion about the company's record achievements in 2024 and its ambitious growth plans for 2025. Becker detailed the production of over 630 metric tons of iodine last year, including a 13% year-over-year increase. He highlighted that the new IO#10 plant, which reached full capacity in late 2024, will contribute significantly to this year's output. The company is also making strides with IO#11, set to begin production in Q3 2025, and ongoing discussions for IO#12, signalling further expansion. Becker emphasised strong global iodine demand, with prices climbing above $70 per kilogram, benefiting Iofina's operations. Despite minor shipping delays pushing sales into 2025, Becker assured investors of continued growth and progress. He also celebrated the company's safety track record, with no lost-time accidents since 2021. Stay tuned for more updates on Iofina PLC and its plans for the future. Don’t forget to like the video, subscribe to Proactive’s YouTube channel, and enable notifications for future updates!" #Iofina #IodineProduction #ChemicalIndustry #BusinessGrowth #RecordProduction #IO10Plant #IO11Plant #GlobalDemand #ChemicalSafety #ProactiveInvestors…
P
Proactive - Interviews for investors
1 Lisata Therapeutics CEO David Mazzo on ASCEND and iLSTA trial results 6:32
6:32
Spill senere
Spill senere
Lister
Lik
Likt
6:32Lisata Therapeutics Inc (NASDAQ:LSTA) CEO David Mazzo joined Proactive's Stephen Gunnion with an update on the company's pancreatic cancer trials. The company recently announced preliminary results from its ASCEND phase 2 trial at the ASCO Gastrointestinal Conference. According to Mazzo, data from the randomized, double-blind, placebo-controlled Cohort A group demonstrated promising trends in overall survival and efficacy. He highlighted that four complete responses were observed in the Certepetide group out of 63 patients—a stark contrast to zero in the standard care group. This is particularly significant when compared to other trials, such as NAPOLI-3, which had only one complete response in nearly 400 patients. Mazzo also discussed Cohort B, which investigates a double-dose regimen of Certepetide to explore pharmacodynamic improvements and optimize treatment efficacy. In addition, Lisata released preliminary data from its iLSTA trial, which examines combining Certepetide with immunotherapy (Durvalumab) and cytotoxics for pancreatic cancer. Mazzo emphasized increased T-cell tumor penetration and higher partial response rates in early data, suggesting potential for enhanced treatment outcomes. Catch the full interview to learn more about these breakthroughs. Visit Proactive’s YouTube channel for updates, like this video, subscribe, and enable notifications to stay informed. #LisataTherapeutics #PancreaticCancer #ClinicalTrials #ASCENDTrial #Certepetide #CancerResearch #Immunotherapy #PharmaNews #BiotechInnovations #ProactiveInvestors…
P
Proactive - Interviews for investors
1 ImmuPharma CEO Tim McCarthy shares latest developments with P140 platform, road ahead 12:35
12:35
Spill senere
Spill senere
Lister
Lik
Likt
12:35ImmuPharma PLC (AIM:IMM) CEO Tim McCarthy joined Stephen Gunnion in the Proactive studio to discuss the company’s recent groundbreaking developments in autoimmune disease treatment. He highlighted the progress made with their P140 platform, emphasising its potential to address multiple autoimmune diseases and transform patient care. McCarthy explained, “This is a breakthrough in a lot of different ways,” referencing recent preclinical findings that allow the identification and categorisation of autoimmune diseases, paving the way for personalised medicine. He also noted the significant interest in P140 from major pharmaceutical companies, underlining its potential to deliver effective treatment without adverse effects. Additionally, McCarthy shared updates from the JP Morgan and Biotech Showcase conferences, where these advancements were presented to key industry players. ImmuPharma’s focus in 2025 includes expanding its partnerships and delivering on its transformative pipeline. Stay tuned for more updates on ImmuPharma’s innovations in the biotech space. Visit Proactive’s YouTube channel for more videos, and don’t forget to like, subscribe, and turn on notifications for future content. #ImmuPharma #AutoimmuneDiseases #P140Platform #PersonalizedMedicine #Biotech #TimMcCarthy #PharmaceuticalInnovation #LupusTreatment #CIDP #HealthcareRevolution…
P
Proactive - Interviews for investors
1 Giyani Metals announces 'transformative' SEZ licence in Botwana for commerical managanese plant 4:24
4:24
Spill senere
Spill senere
Lister
Lik
Likt
4:24Giyani Metals Corp (TSX-V:EMM, OTC:CATPF) CEO Charles FitzRoy joined Proactive's Stephen Gunnion with news that the company has secured a 50-year Special Economic Zone (SEZ) Investor License for its battery-grade manganese (HPMSM) commercial plant site to be built in Botswana. The award of the SEZ License designates Giyani’s Commercial Plant as a Single Factory Special Economic Zone. The Commercial Plant will be located adjacent to its K.Hill manganese mine site, near Kanye, Botswana. FitzRoy said securing the SEZ License for its Commercial Plant is a transformative step for Giyani, and an important milestone on its path to becoming a leading producer of battery-grade manganese, particularly as its Demo Plant nears first production.…
Velkommen til Player FM!
Player FM scanner netter for høykvalitets podcaster som du kan nyte nå. Det er den beste podcastappen og fungerer på Android, iPhone og internett. Registrer deg for å synkronisere abonnement på flere enheter.